Michael R. Galambos

Michael R. Galambos

Gastroenterology | Hepatology

95 Collier Rd NW
Suite 4085
Atlanta, GA 30309

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3 publications

Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

Journal: Alimentary pharmacology & therapeutics

Published: July 28, 2023

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.

Journal: Journal of hepatology

Published: July 27, 2021

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.

Journal: The lancet. Gastroenterology & hepatology

Published: May 21, 2017

Showing 1-3 of 3

Last Updated: 09/26/2026